

Cervical Ripening Drugs Market, 2012 to 2023

<https://marketpublishers.com/r/C253DE620F4EN.html>

Date: December 2017

Pages: 201

Price: US\$ 4,400.00 (Single User License)

ID: C253DE620F4EN

Abstracts

Market Outline: Cervical Ripening Drugs Market

Cervical ripening is defined as the softening of cervix prior to onset of labor contractions and it is necessary for the cervical dilation and passage of fetus. Cervix softens, thins, dilates, and relaxes in response to the uterine contractions and allows the cervix to easily pass over the fetal part during labor. Cervical ripening drugs are used before the induction of labor for the dilatation of cervix. The ripening of cervix is associated with the reduced collagen fiber strength, decrease in collagen fiber alignment, and diminished the tensile strength of extracellular cervical matrix. The common techniques used for the cervical ripening are mechanical interventions such as insertion of cervical catheters and dilators and application of cervical ripening agents such as prostaglandins.

Market Dynamics: Cervical Ripening Drugs Market

Growing usage of cervical ripening drugs before the induction of labor, rise in R&D activities for the innovation of newer drugs, increase in awareness about cervical ripening drugs in developed and developing countries, low cost of drugs, and government initiations for improving the baby deliveries are anticipated to fuel the cervical ripening drugs market over the forecast period. However, stringent regulatory policies for product approval, adverse effects associated with the cervical ripening drugs, and alternative procedures for the childbirth are expected to hinder the growth of surgical ripening drugs market over the forecast timeframe.

Market Scope: Cervical Ripening Drugs Market

Cervical ripening drugs market is segmented on the basis of drug type, route of administration, distribution channel, and region

Based on the drug type, market is segmented into the following:

- Prostaglandins
- Oxytocin
- Progesterone Receptor Antagonists
- Relaxin
- Estrogen
- Others

Based on the route of administration, market is segmented into the following:

- Oral
- Intravenous
- Vaginal

Based on the distribution channel, market is segmented into the following:

- Hospital Pharmacies
- Retail Pharmacies
- Others

Market Summary: Cervical Ripening Drugs Market

Cervical ripening drugs market is projected to grow at a significant rate with increase in the usage of cervical ripening drugs prior to the induction of labor. Moreover, acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by market players to generate increased revenue in cervical ripening drugs market. For instance, in February 2012, Ferring Pharmaceuticals acquired Cytokine PharmaSciences Inc. and the acquisition includes manufacturing assets of Cervidil (Dinoprostone) in U.S. and Canada.

Regional Analysis: Cervical Ripening Drugs Market

Geographically, global cervical ripening drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America cervical ripening drugs market growth driven by increase in the R&D for the innovation of newer drugs and high awareness about the cervical ripening drugs among the physicians. Europe cervical ripening drugs market has a lucrative growth owing to high adoption of cervical ripening drugs, launching of newer drugs by the market players. Asia Pacific cervical ripening drugs market has significant share owing to rise in number of female

population, government initiations for the baby birth, and increase in the using of cervical ripening drugs before the induction of labor are propel the market. Middle East and Africa cervical ripening drugs market has a prominent share owing to increase in the number of births and rise in awareness about the cervical ripening drugs are in the region.

Competition Assessment: Cervical Ripening Drugs Market

Some of the players in the global cervical ripening drugs market include:

Ferring B.V. (Switzerland)
Azanta A/S (Denmark)
Novartis AG (Switzerland)
GlaxoSmithKline plc (U.K.)
AstraZeneca plc (U.K.)
Pfizer, Inc. (U.S.)
Bayer AG (Germany)

Notable Market Developments: Cervical Ripening Drugs Market

In February 2016, Azanta A/S filed marketing authorization application in Nordic countries for Angusta (Misoprostol), which is indicated in induction of labor

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CERVICAL RIPENING DRUGS MARKET INTRODUCTION

2.1. Global Cervical Ripening Drugs Market – Taxonomy

2.2. Global Cervical Ripening Drugs Market –Definitions

2.2.1. Drug class

2.2.2. Distribution Channel

3. GLOBAL CERVICAL RIPENING DRUGS MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Cervical Ripening Drugs Market Dynamics – Factors Impact Analysis

3.6. Global Cervical Ripening Drugs Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Cervical Ripening Drugs Market – Product Innovations

4. GLOBAL CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL CERVICAL RIPENING DRUGS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

5.1.1. Prostaglandins

5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.1.3. Market Opportunity Analysis

5.1.2. Oxytocin

5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

5.1.3. Progesterone Receptor Antagonists

5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

5.1.4. Relaxin

5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.4.3. Market Opportunity Analysis

5.1.5. Estrogen

5.1.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.5.3. Market Opportunity Analysis

5.1.6. Others

5.1.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.6.3. Market Opportunity Analysis

6. GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1.1. Oral

6.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.1.3. Market Opportunity Analysis

6.1.2. Intravenous

6.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.2.3. Market Opportunity Analysis

6.2. Vaginal

6.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.1.3. Market Opportunity Analysis

7. MARKET OPPORTUNITY ANALYSIS GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Others

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

8. GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.5.3. Market Opportunity Analysis

8.6. Global Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Diseases Type, Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Prostaglandins

9.1.1.2. Oxytocin

9.1.1.3. Progesterone Receptor Antagonists

9.1.1.4. Relaxin

9.1.1.5. Estrogen

9.1.1.6. Others

9.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Oral

9.1.2.2. Intravenous

9.1.2.3. Vaginal

9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospital Pharmacies

9.1.3.2. Retail Pharmacies

9.1.3.3. Others

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Cervical Ripening Drugs Market - Opportunity Analysis Index, By

Drug Class, Route of Administration, Distribution Channel and Country, 2017 – 2023

9.1.6. North America Cervical Ripening Drugs Market Dynamics – Trends

10. EUROPE CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.2.1. Prostaglandins

10.1.2.2. Oxytocin

10.1.2.3. Progesterone Receptor Antagonists

10.1.2.4. Relaxin

10.1.2.5. Estrogen

10.1.2.6. Others

10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Oral

10.1.3.2. Intravenous

10.1.3.3. Vaginal

10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Hospital Pharmacies

10.1.4.2. Retail Pharmacies

10.1.4.3. Others

10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.5.1. Germany

10.1.5.2. UK

10.1.5.3. France

10.1.5.4. Spain

10.1.5.5. Italy

10.1.5.6. Russia

10.1.5.7. Poland

10.1.5.8. Rest of Europe

10.1.6. Europe Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023

10.1.7. Europe Cervical Ripening Drugs Market Dynamics – Trends

11. ASIA-PACIFIC CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.2.1. Prostaglandins

11.1.2.2. Oxytocin

11.1.2.3. Progesterone Receptor Antagonists

11.1.2.4. Relaxin

11.1.2.5. Estrogen

11.1.2.6. Others

11.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Oral

11.1.3.2. Intravenous

11.1.3.3. Vaginal

11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.4.1. Hospital Pharmacies

11.1.4.2. Retail Pharmacies

11.1.4.3. Others

11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.1.5.1. Japan

11.1.5.2. China

11.1.5.3. India

11.1.5.4. ASEAN

11.1.5.5. Australia & New Zealand

11.1.5.6. Rest of Asia-Pacific

11.1.6. Asia-Pacific Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023

11.1.7. Europe Cervical Ripening Drugs Market Dynamics – Trends

12. LATIN AMERICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.2.1. Prostaglandins

12.1.2.2. Oxytocin

12.1.2.3. Progesterone Receptor Antagonists

12.1.2.4. Relaxin

12.1.2.5. Estrogen

12.1.2.6. Others

12.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Oral

12.1.3.2. Intravenous

12.1.3.3. Vaginal

12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Hospital Pharmacies

12.1.4.2. Retail Pharmacies

12.1.4.3. Others

12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.5.1. Brazil

12.1.5.2. Mexico

12.1.5.3. Argentina

12.1.5.4. Venezuela

12.1.5.5. Rest of Latin America

12.1.6. Latin America Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023

12.1.7. Latin America Cervical Ripening Drugs Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 13.1.2.1. Prostaglandins
- 13.1.2.2. Oxytocin
- 13.1.2.3. Progesterone Receptor Antagonists
- 13.1.2.4. Relaxin
- 13.1.2.5. Estrogen
- 13.1.2.6. Others
- 13.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.3.1. Oral
 - 13.1.3.2. Intravenous
 - 13.1.3.3. Vaginal
- 13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.4.1. Hospital Pharmacies
 - 13.1.4.2. Retail Pharmacies
 - 13.1.4.3. Others
- 13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 13.1.5.1. Gulf Cooperation Council (GCC) Countries
 - 13.1.5.2. Israel
 - 13.1.5.3. South Africa
 - 13.1.5.4. Rest of MEA
- 13.1.6. MEA Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
- 13.1.7. MEA Cervical Ripening Drugs Market Dynamics – Trends

14. COMPETITION LANDSCAPE

- 14.1. Strategic Dashboard of Top Market Players
- 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
 - 14.2.1. Ferring B.V. (Switzerland)
 - 14.2.2. Azanta A/S (Denmark)
 - 14.2.3. Novartis AG (Switzerland)
 - 14.2.4. GlaxoSmithKline plc (U.K.)
 - 14.2.5. AstraZeneca plc (U.K.)
 - 14.2.6. Pfizer, Inc. (U.S.)
 - 14.2.7. Bayer AG (Germany)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Cervical Ripening Drugs Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/C253DE620F4EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C253DE620F4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970